U.S. Stock Market Midday Update

Chemomab Therapeutics fell 22.45%. Based on recent key news:

1. On July 8, Chemomab Therapeutics reached a merger agreement with Scipher, aiming to advance the Phase II rheumatoid arthritis trial of the anti-CCL24 antibody. The merged company is expected to have sufficient funds to operate until the second half of 2028. This news led to significant stock price fluctuations.

2. On July 8, the merged company will receive approximately $30 million in new financing, primarily from investors such as Northpond Ventures and Khosla Ventures. This move further enhances market confidence in the company's future development, although stock prices still experienced fluctuations in the short term.

3. On July 8, Chemomab Therapeutics' stock price fell 13.72% in pre-market trading on Nasdaq, reflecting the market's complex reaction to the merger news. The biotechnology sector has recently shown significant volatility, and investors should exercise caution.

Stocks with High Trading Volume in the Industry

Gilead Sciences fell 0.54%. Based on recent key news:

1. On July 6, HSBC upgraded Gilead Sciences' rating from "Hold" to "Buy," raising the target price from $133 to $155. This rating upgrade reflects market confidence in Gilead's future performance, driving the stock price up.

2. On July 8, Gilead Sciences completed an acquisition worth $780 million, further solidifying its position in the biotechnology sector. This move was seen as a positive signal by the market, promoting stock price stability.

3. In the past 90 days, company insiders sold over 83,000 shares of stock, valued at approximately $10.82 million. This insider selling behavior triggered negative sentiment in the market, leading to stock price fluctuations. The biotechnology sector has shown strong performance recently, with significant capital inflows.

AbbVie fell 0.37%. Based on recent key news:

1. On July 7, the European Commission approved AbbVie's TEPKINLY combination therapy for the treatment of relapsed or refractory follicular lymphoma. This approval was based on Phase III trial data, showing that the therapy significantly reduces the risk of disease progression or death by 79%, driving stock price fluctuations.

2. On July 6, Cantor Fitzgerald raised AbbVie's target stock price from $240 to $265, reflecting market confidence in its future growth, impacting stock price trends.

3. On July 6, AbbVie expected its second-quarter results to include $291 million in research and milestone expenses, affecting earnings per share and leading to stock price fluctuations. The pharmaceutical industry's innovative drug sales have shown significant growth.

Moderna fell 6.16%, with increased trading volume. Based on recent key news:

1. On July 6, Moderna's stock price reached a 52-week high due to support from the FDA advisory committee for its flu vaccine. The stock strengthened after updates to the vaccine pipeline, but the target price remained below the current price, leading to adjustments in market expectations and stock price fluctuations.

2. On July 7, the market adjusted its earnings expectations for Moderna due to unclear vaccine sales prospects, causing fluctuations in investor sentiment and a decline in stock price.

3. On July 8, macroeconomic policies remained neutral, having no direct impact on Moderna, but overall market sentiment fluctuated, affecting stock performance. The vaccine industry faces policy support and adjustments in market expectations.

Stocks Ranked Among the Top by Market Capitalization in the Industry

Amgen rose by 0.31%. Based on recent key news:

1. On July 8, Amgen signed a memorandum of cooperation with the International Clinical Trial Center of the Guangdong-Hong Kong-Macao Greater Bay Area, aimed at enhancing medical capabilities in Hong Kong and the Greater Bay Area. This collaboration will promote scientific research exchange and innovation, improve clinical treatment levels, and boost market confidence, resulting in a rise in stock price.

2. On July 6, analysts adjusted the target price for Amgen's stock, with the average target price rising from $352.35 to $355.04, reflecting optimistic market expectations for its future performance and supporting the rise in stock price.

3. On July 7, Amgen's annualized return over the past 15 years has exceeded the market average, demonstrating its long-term investment value, further enhancing investor confidence and driving up the stock price. The biotechnology industry is accelerating innovative collaborations, and the market is optimistic